Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Research Report, Competitive, Technology and Forecast Analysis 2025-2032
Description
Market Overview
According to DIResearch's in-depth investigation and research, the global Chemotherapy Induced Peripheral Neuropathy Treatment market size will reach 2,141.48 Million USD in 2025 and is projected to reach 3,241.32 Million USD by 2032, with a CAGR of 6.10% (2025-2032). Notably, the China Chemotherapy Induced Peripheral Neuropathy Treatment market has changed rapidly in the past few years. By 2025, China's market size is expected to be Million USD, representing approximately % of the global market share.
Research Summary
Chemotherapy-induced peripheral neuropathy (CIPN) treatment refers to various approaches aimed at managing and alleviating the symptoms of nerve damage caused by chemotherapy drugs. CIPN is a common side effect of certain chemotherapy medications, leading to tingling, numbness, pain, and weakness in the hands and feet. The treatment options for CIPN focus on symptom relief and improving the patient's quality of life. Medications such as pain relievers, antidepressants, and anticonvulsants may be prescribed to manage nerve pain. Physical therapy and occupational therapy can help improve muscle strength and function and teach patients strategies to cope with daily challenges. Additionally, lifestyle modifications, such as regular exercise, maintaining a healthy diet, and avoiding activities that worsen symptoms, may also be recommended. As CIPN can vary in severity and persistence, the treatment approach is tailored to each patient's individual needs and the specific chemotherapy drugs involved, aiming to minimize discomfort and maximize functionality during and after cancer treatment.
The major global suppliers of Chemotherapy Induced Peripheral Neuropathy Treatment include Aptinyx Inc, Asahi Kasei Pharma Corp, Regenacy Pharmaceuticals, MAKScientific LLC, Metys Pharmaceuticals AG, Nemus Bioscience Inc, PledPharma, Sova Pharmaceuticals Inc, DermaXon LLC, Krenitsky Pharmaceuticals Inc, Kineta Inc, PeriphaGen, Apexian Pharma, WinSanTor, etc. The global players competition landscape in this report is divided into three tiers. The first tier comprises global leading enterprises that command a substantial market share, hold a dominant industry position, possess strong competitiveness and influence, and generate significant revenue. The second tier includes companies with a notable market presence and reputation; these firms actively follow industry leaders in product, service, or technological innovation and maintain a moderate revenue scale. The third tier consists of smaller companies with limited market share and lower brand recognition, primarily focused on local markets and generating comparatively lower revenue.
This report studies the market size, price trends and future development prospects of Chemotherapy Induced Peripheral Neuropathy Treatment. Focus on analysing the market share, product portfolio, prices, sales, revenue and gross profit margin of global major suppliers, as well as the market status and trends of different product types and applications in the global Chemotherapy Induced Peripheral Neuropathy Treatment market. The report data covers historical data from 2020 to 2024, based year in 2025 and forecast data from 2026 to 2032.
The regions and countries in the report include US, Germany, Japan, China, France, UK, South Korea, Canada, Italy, Russia, Mexico, Brazil, India, Vietnam, Thailand, South Africa and other regions, covering the Chemotherapy Induced Peripheral Neuropathy Treatment market conditions and future development trends of key regions and countries, combined with industry-related policies and the latest technological developments, analyze the development characteristics of Chemotherapy Induced Peripheral Neuropathy Treatment industries in various regions and countries, help companies understand the development characteristics of each region, help companies formulate business strategies, and achieve the ultimate goal of the company's global development strategy.
The data sources of this report mainly include the National Bureau of Statistics, customs databases, industry associations, corporate financial reports, third-party databases, etc. Among them, macroeconomic data mainly comes from the National Bureau of Statistics, International Economic Research Organization; industry statistical data mainly come from industry associations; company data mainly comes from interviews, public information collection, third-party reliable databases, and price data mainly comes from various markets monitoring database.
Global Key Suppliers of Chemotherapy Induced Peripheral Neuropathy Treatment Include:
Aptinyx Inc
Asahi Kasei Pharma Corp
Regenacy Pharmaceuticals
MAKScientific LLC
Metys Pharmaceuticals AG
Nemus Bioscience Inc
PledPharma
Sova Pharmaceuticals Inc
DermaXon LLC
Krenitsky Pharmaceuticals Inc
Kineta Inc
PeriphaGen
Apexian Pharma
WinSanTor
Chemotherapy Induced Peripheral Neuropathy Treatment Product Segment Include:
Calcium Channel α2-delta Ligands
Antidepressants
Opioids
Others
Chemotherapy Induced Peripheral Neuropathy Treatment Product Application Include:
Platinum Agents
Taxanes
Vinca Alkaloids
Others
Chapter Scope
Chapter 1: Product Research Range, Product Types and Applications, Market Overview, Market Situation and Trend
Chapter 2: Global Chemotherapy Induced Peripheral Neuropathy Treatment Industry PESTEL Analysis
Chapter 3: Global Chemotherapy Induced Peripheral Neuropathy Treatment Industry Porter's Five Forces Analysis
Chapter 4: Global Chemotherapy Induced Peripheral Neuropathy Treatment Major Regional Market Size (Revenue) and Forecast Analysis
Chapter 5: Global Chemotherapy Induced Peripheral Neuropathy Treatment Competitive Analysis of Key Suppliers (Revenue, Market Share, Regional Distribution and Industry Concentration)
Chapter 6: Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue and Forecast Analysis by Product Type
Chapter 7: Key Company Profiles (Product Portfolio, Revenue and Gross Margin)
Chapter 8: Industrial Chain Analysis, Chemotherapy Induced Peripheral Neuropathy Treatment Different Application Market Analysis (Revenue and Forecast) and Sales Channel Analysis
Chapter 9: Research Findings and Conclusion
Chapter 10: Methodology and Data Sources
According to DIResearch's in-depth investigation and research, the global Chemotherapy Induced Peripheral Neuropathy Treatment market size will reach 2,141.48 Million USD in 2025 and is projected to reach 3,241.32 Million USD by 2032, with a CAGR of 6.10% (2025-2032). Notably, the China Chemotherapy Induced Peripheral Neuropathy Treatment market has changed rapidly in the past few years. By 2025, China's market size is expected to be Million USD, representing approximately % of the global market share.
Research Summary
Chemotherapy-induced peripheral neuropathy (CIPN) treatment refers to various approaches aimed at managing and alleviating the symptoms of nerve damage caused by chemotherapy drugs. CIPN is a common side effect of certain chemotherapy medications, leading to tingling, numbness, pain, and weakness in the hands and feet. The treatment options for CIPN focus on symptom relief and improving the patient's quality of life. Medications such as pain relievers, antidepressants, and anticonvulsants may be prescribed to manage nerve pain. Physical therapy and occupational therapy can help improve muscle strength and function and teach patients strategies to cope with daily challenges. Additionally, lifestyle modifications, such as regular exercise, maintaining a healthy diet, and avoiding activities that worsen symptoms, may also be recommended. As CIPN can vary in severity and persistence, the treatment approach is tailored to each patient's individual needs and the specific chemotherapy drugs involved, aiming to minimize discomfort and maximize functionality during and after cancer treatment.
The major global suppliers of Chemotherapy Induced Peripheral Neuropathy Treatment include Aptinyx Inc, Asahi Kasei Pharma Corp, Regenacy Pharmaceuticals, MAKScientific LLC, Metys Pharmaceuticals AG, Nemus Bioscience Inc, PledPharma, Sova Pharmaceuticals Inc, DermaXon LLC, Krenitsky Pharmaceuticals Inc, Kineta Inc, PeriphaGen, Apexian Pharma, WinSanTor, etc. The global players competition landscape in this report is divided into three tiers. The first tier comprises global leading enterprises that command a substantial market share, hold a dominant industry position, possess strong competitiveness and influence, and generate significant revenue. The second tier includes companies with a notable market presence and reputation; these firms actively follow industry leaders in product, service, or technological innovation and maintain a moderate revenue scale. The third tier consists of smaller companies with limited market share and lower brand recognition, primarily focused on local markets and generating comparatively lower revenue.
This report studies the market size, price trends and future development prospects of Chemotherapy Induced Peripheral Neuropathy Treatment. Focus on analysing the market share, product portfolio, prices, sales, revenue and gross profit margin of global major suppliers, as well as the market status and trends of different product types and applications in the global Chemotherapy Induced Peripheral Neuropathy Treatment market. The report data covers historical data from 2020 to 2024, based year in 2025 and forecast data from 2026 to 2032.
The regions and countries in the report include US, Germany, Japan, China, France, UK, South Korea, Canada, Italy, Russia, Mexico, Brazil, India, Vietnam, Thailand, South Africa and other regions, covering the Chemotherapy Induced Peripheral Neuropathy Treatment market conditions and future development trends of key regions and countries, combined with industry-related policies and the latest technological developments, analyze the development characteristics of Chemotherapy Induced Peripheral Neuropathy Treatment industries in various regions and countries, help companies understand the development characteristics of each region, help companies formulate business strategies, and achieve the ultimate goal of the company's global development strategy.
The data sources of this report mainly include the National Bureau of Statistics, customs databases, industry associations, corporate financial reports, third-party databases, etc. Among them, macroeconomic data mainly comes from the National Bureau of Statistics, International Economic Research Organization; industry statistical data mainly come from industry associations; company data mainly comes from interviews, public information collection, third-party reliable databases, and price data mainly comes from various markets monitoring database.
Global Key Suppliers of Chemotherapy Induced Peripheral Neuropathy Treatment Include:
Aptinyx Inc
Asahi Kasei Pharma Corp
Regenacy Pharmaceuticals
MAKScientific LLC
Metys Pharmaceuticals AG
Nemus Bioscience Inc
PledPharma
Sova Pharmaceuticals Inc
DermaXon LLC
Krenitsky Pharmaceuticals Inc
Kineta Inc
PeriphaGen
Apexian Pharma
WinSanTor
Chemotherapy Induced Peripheral Neuropathy Treatment Product Segment Include:
Calcium Channel α2-delta Ligands
Antidepressants
Opioids
Others
Chemotherapy Induced Peripheral Neuropathy Treatment Product Application Include:
Platinum Agents
Taxanes
Vinca Alkaloids
Others
Chapter Scope
Chapter 1: Product Research Range, Product Types and Applications, Market Overview, Market Situation and Trend
Chapter 2: Global Chemotherapy Induced Peripheral Neuropathy Treatment Industry PESTEL Analysis
Chapter 3: Global Chemotherapy Induced Peripheral Neuropathy Treatment Industry Porter's Five Forces Analysis
Chapter 4: Global Chemotherapy Induced Peripheral Neuropathy Treatment Major Regional Market Size (Revenue) and Forecast Analysis
Chapter 5: Global Chemotherapy Induced Peripheral Neuropathy Treatment Competitive Analysis of Key Suppliers (Revenue, Market Share, Regional Distribution and Industry Concentration)
Chapter 6: Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue and Forecast Analysis by Product Type
Chapter 7: Key Company Profiles (Product Portfolio, Revenue and Gross Margin)
Chapter 8: Industrial Chain Analysis, Chemotherapy Induced Peripheral Neuropathy Treatment Different Application Market Analysis (Revenue and Forecast) and Sales Channel Analysis
Chapter 9: Research Findings and Conclusion
Chapter 10: Methodology and Data Sources
Table of Contents
165 Pages
- 1 Chemotherapy Induced Peripheral Neuropathy Treatment Market Overview
- 1.1 Product Definition and Statistical Scope
- 1.2 Chemotherapy Induced Peripheral Neuropathy Treatment Product by Type
- 1.2.1 Calcium Channel α2-delta Ligands
- 1.2.2 Antidepressants
- 1.2.3 Opioids
- 1.2.4 Others
- 1.3 Chemotherapy Induced Peripheral Neuropathy Treatment Product by Application
- 1.3.1 Platinum Agents
- 1.3.2 Taxanes
- 1.3.3 Vinca Alkaloids
- 1.3.4 Others
- 1.4 Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Size Analysis (2020-2032)
- 1.5 Chemotherapy Induced Peripheral Neuropathy Treatment Market Development Status and Trends
- 1.5.1 Chemotherapy Induced Peripheral Neuropathy Treatment Industry Development Status Analysis
- 1.5.2 Chemotherapy Induced Peripheral Neuropathy Treatment Industry Development Trends Analysis
- 2 Chemotherapy Induced Peripheral Neuropathy Treatment Market PESTEL Analysis
- 2.1 Political Factors Analysis
- 2.2 Economic Factors Analysis
- 2.3 Social Factors Analysis
- 2.4 Technological Factors Analysis
- 2.5 Environmental Factors Analysis
- 2.6 Legal Factors Analysis
- 3 Chemotherapy Induced Peripheral Neuropathy Treatment Market Porter's Five Forces Analysis
- 3.1 Competitive Rivalry
- 3.2 Threat of New Entrants
- 3.3 Bargaining Power of Suppliers
- 3.4 Bargaining Power of Buyers
- 3.5 Threat of Substitutes
- 4 Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Analysis by Country
- 4.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Size Analysis by Country: 2024 VS 2025 VS 2032
- 4.1.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Analysis by Country (2020-2025)
- 4.1.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Forecast Analysis by Country (2026-2032)
- 4.2 United States Chemotherapy Induced Peripheral Neuropathy Treatment Market Revenue and Growth Rate (2020-2032)
- 4.3 Germany Chemotherapy Induced Peripheral Neuropathy Treatment Market Revenue and Growth Rate (2020-2032)
- 4.4 Japan Chemotherapy Induced Peripheral Neuropathy Treatment Market Revenue and Growth Rate (2020-2032)
- 4.5 China Chemotherapy Induced Peripheral Neuropathy Treatment Market Revenue and Growth Rate (2020-2032)
- 4.6 France Chemotherapy Induced Peripheral Neuropathy Treatment Market Revenue and Growth Rate (2020-2032)
- 4.7 U.K. Chemotherapy Induced Peripheral Neuropathy Treatment Market Revenue and Growth Rate (2020-2032)
- 4.8 South Korea Chemotherapy Induced Peripheral Neuropathy Treatment Market Revenue and Growth Rate (2020-2032)
- 4.9 Canada Chemotherapy Induced Peripheral Neuropathy Treatment Market Revenue and Growth Rate (2020-2032)
- 4.10 Italy Chemotherapy Induced Peripheral Neuropathy Treatment Market Revenue and Growth Rate (2020-2032)
- 4.11 Russia Chemotherapy Induced Peripheral Neuropathy Treatment Market Revenue and Growth Rate (2020-2032)
- 4.12 Mexico Chemotherapy Induced Peripheral Neuropathy Treatment Market Revenue and Growth Rate (2020-2032)
- 4.13 Brazil Chemotherapy Induced Peripheral Neuropathy Treatment Market Revenue and Growth Rate (2020-2032)
- 4.14 India Chemotherapy Induced Peripheral Neuropathy Treatment Market Revenue and Growth Rate (2020-2032)
- 4.15 Vietnam Chemotherapy Induced Peripheral Neuropathy Treatment Market Revenue and Growth Rate (2020-2032)
- 4.16 Thailand Chemotherapy Induced Peripheral Neuropathy Treatment Market Revenue and Growth Rate (2020-2032)
- 4.17 South Africa Chemotherapy Induced Peripheral Neuropathy Treatment Market Revenue and Growth Rate (2020-2032)
- 5 Competition by Suppliers
- 5.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Revenue by Key Suppliers (2021-2025)
- 5.2 Chemotherapy Induced Peripheral Neuropathy Treatment Competitive Landscape Analysis and Market Dynamic
- 5.2.1 Chemotherapy Induced Peripheral Neuropathy Treatment Competitive Landscape Analysis
- 5.2.2 Global Key Suppliers Headquarter and Key Area Sales
- 5.2.3 Market Dynamic
- 6 Chemotherapy Induced Peripheral Neuropathy Treatment Market Analysis by Type
- 6.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Size Analysis by Type: 2024 VS 2025 VS 2032
- 6.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue and Forecast Analysis by Type (2020-2032)
- 7 Key Companies Analysis
- 7.1 Aptinyx Inc
- 7.1.1 Aptinyx Inc Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 7.1.2 Aptinyx Inc Chemotherapy Induced Peripheral Neuropathy Treatment Product Portfolio
- 7.1.3 Aptinyx Inc Chemotherapy Induced Peripheral Neuropathy Treatment Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 7.2 Asahi Kasei Pharma Corp
- 7.2.1 Asahi Kasei Pharma Corp Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 7.2.2 Asahi Kasei Pharma Corp Chemotherapy Induced Peripheral Neuropathy Treatment Product Portfolio
- 7.2.3 Asahi Kasei Pharma Corp Chemotherapy Induced Peripheral Neuropathy Treatment Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 7.3 Regenacy Pharmaceuticals
- 7.3.1 Regenacy Pharmaceuticals Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 7.3.2 Regenacy Pharmaceuticals Chemotherapy Induced Peripheral Neuropathy Treatment Product Portfolio
- 7.3.3 Regenacy Pharmaceuticals Chemotherapy Induced Peripheral Neuropathy Treatment Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 7.4 MAKScientific LLC
- 7.4.1 MAKScientific LLC Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 7.4.2 MAKScientific LLC Chemotherapy Induced Peripheral Neuropathy Treatment Product Portfolio
- 7.4.3 MAKScientific LLC Chemotherapy Induced Peripheral Neuropathy Treatment Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 7.5 Metys Pharmaceuticals AG
- 7.5.1 Metys Pharmaceuticals AG Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 7.5.2 Metys Pharmaceuticals AG Chemotherapy Induced Peripheral Neuropathy Treatment Product Portfolio
- 7.5.3 Metys Pharmaceuticals AG Chemotherapy Induced Peripheral Neuropathy Treatment Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 7.6 Nemus Bioscience Inc
- 7.6.1 Nemus Bioscience Inc Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 7.6.2 Nemus Bioscience Inc Chemotherapy Induced Peripheral Neuropathy Treatment Product Portfolio
- 7.6.3 Nemus Bioscience Inc Chemotherapy Induced Peripheral Neuropathy Treatment Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 7.7 PledPharma
- 7.7.1 PledPharma Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 7.7.2 PledPharma Chemotherapy Induced Peripheral Neuropathy Treatment Product Portfolio
- 7.7.3 PledPharma Chemotherapy Induced Peripheral Neuropathy Treatment Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 7.8 Sova Pharmaceuticals Inc
- 7.8.1 Sova Pharmaceuticals Inc Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 7.8.2 Sova Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Product Portfolio
- 7.8.3 Sova Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 7.9 DermaXon LLC
- 7.9.1 DermaXon LLC Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 7.9.2 DermaXon LLC Chemotherapy Induced Peripheral Neuropathy Treatment Product Portfolio
- 7.9.3 DermaXon LLC Chemotherapy Induced Peripheral Neuropathy Treatment Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 7.10 Krenitsky Pharmaceuticals Inc
- 7.10.1 Krenitsky Pharmaceuticals Inc Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 7.10.2 Krenitsky Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Product Portfolio
- 7.10.3 Krenitsky Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 7.11 Kineta Inc
- 7.11.1 Kineta Inc Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 7.11.2 Kineta Inc Chemotherapy Induced Peripheral Neuropathy Treatment Product Portfolio
- 7.11.3 Kineta Inc Chemotherapy Induced Peripheral Neuropathy Treatment Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 7.12 PeriphaGen
- 7.12.1 PeriphaGen Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 7.12.2 PeriphaGen Chemotherapy Induced Peripheral Neuropathy Treatment Product Portfolio
- 7.12.3 PeriphaGen Chemotherapy Induced Peripheral Neuropathy Treatment Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 7.13 Apexian Pharma
- 7.13.1 Apexian Pharma Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 7.13.2 Apexian Pharma Chemotherapy Induced Peripheral Neuropathy Treatment Product Portfolio
- 7.13.3 Apexian Pharma Chemotherapy Induced Peripheral Neuropathy Treatment Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 7.14 WinSanTor
- 7.14.1 WinSanTor Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 7.14.2 WinSanTor Chemotherapy Induced Peripheral Neuropathy Treatment Product Portfolio
- 7.14.3 WinSanTor Chemotherapy Induced Peripheral Neuropathy Treatment Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 8 Industry Chain Analysis
- 8.1 Chemotherapy Induced Peripheral Neuropathy Treatment Industry Chain Analysis
- 8.2 Chemotherapy Induced Peripheral Neuropathy Treatment Product Downstream Application Analysis
- 8.2.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Size and Growth Rate (CAGR) by Application: 2024 VS 2025 VS 2032
- 8.2.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue and Forecast by Application (2020-2032)
- 8.3 Chemotherapy Induced Peripheral Neuropathy Treatment Typical Downstream Customers
- 8.4 Chemotherapy Induced Peripheral Neuropathy Treatment Sales Channel Analysis
- 9 Research Findings and Conclusion
- 10 Methodology and Data Source
- 10.1 Methodology/Research Approach
- 10.2 Research Scope
- 10.3 Benchmarks and Assumptions
- 10.4 Date Source
- 10.4.1 Primary Sources
- 10.4.2 Secondary Sources
- 10.5 Data Cross Validation
- 10.6 Disclaimer
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
